Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01526005 · ClinicalTrials.gov registry record

Brain Nicotine Receptor Density & Response to Nicotine Patch

A clinical trial of Cigarette Smoking, sponsored by Brentwood Biomedical Research Institute.

Completed
Registry status
50
Enrollment target
1
Study location

NCT01526005: Completed study of Cigarette Smoking, sponsored by Brentwood Biomedical Research Institute.

NCT01526005 is a study of Cigarette Smoking that has completed, run by Brentwood Biomedical Research Institute. The registered enrollment target is 50 participants, below the 175-participant average among 45 other Cigarette Smoking trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01526005, a study of Cigarette Smoking, has completed, sponsored by Brentwood Biomedical Research Institute.

COMPLETED
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

Even though the health risks and societal costs of cigarette smoking are well-known, roughly 19.8% of American adults continue to smoke. While most smokers endorse a desire to quit, very few (\< 5%) will actually quit in a given year without treatment, and only about 20-25% achieve abstinence after 6 months or more of effective treatment. Therefore, there continues to be a vital need to improve outcomes for cigarette smokers seeking treatment. Current first-line medications for Tobacco Dependence include nicotine replacement therapies (such as the patch, gum, lozenge, nasal spray, and inhaler), varenicline HCl (Chantix), and bupropion HCl (Zyban), with the current standard of care in most treatment settings being to choose specific medications based primarily on availability, ease of use, and patient preference. The goal of the proposed research is to improve the delivery of smoking cessation treatment by determining if pre-treatment nicotine receptor density in cigarette smokers is associated with smoking cessation outcome with the standard nicotine patch taper. The study's main hypothesis is that cigarette smokers with less pre-treatment upregulation of nicotine receptors will have a greater likelihood of quitting smoking from a standard course of nicotine patch treatment than smokers with more up-regulation of these receptors. Positron emission tomography (PET) will be used to test this hypothesis.

Primary Outcome

Brain imaging used to predict response to smoking cessation treatment

Conditions Studied

Cigarette Smoking

Interventions

  • DRUG Transdermal Nicotine Patch
  • DRUG Transdermal Placebo Patch

Study Locations (1)

California

  • West Los Angeles Veterans Affairs Medical Center - Los Angeles

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2012-03
Brentwood Biomedical Research Institute

3 total trials

What the finished NCT01526005 record still lists

NCT01526005 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 175-participant average among 45 other Cigarette Smoking trials with a reported enrollment target (71% lower).

The record links to 1 condition, with Cigarette Smoking appearing as the primary indexed condition, and to 2 interventions - of which Transdermal Nicotine Patch is the first listed.

NCT01526005 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT01526005 about?

NCT01526005 is a clinical study titled "Brain Nicotine Receptor Density & Response to Nicotine Patch". Even though the health risks and societal costs of cigarette smoking are well-known, roughly 19.8% of American adults continue to smoke. While most smokers endorse a desire to quit, very few (\< 5%) will actually quit in a given year without treatment, and only about 20-25% achieve abstinence after ...

What is the current status of trial NCT01526005?

This trial is currently completed. The enrollment target is 50 participants. The study started on 2012-03.

What conditions does trial NCT01526005 study?

This clinical trial studies the following conditions: Cigarette Smoking.

What interventions are being tested in trial NCT01526005?

The interventions under investigation include: Transdermal Nicotine Patch (DRUG), Transdermal Placebo Patch (DRUG).

Who is sponsoring clinical trial NCT01526005?

This trial is sponsored by Brentwood Biomedical Research Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01526005 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cigarette Smoking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01526005's enrollment target sits among peer trials

50 32nd of 45 higher than 13 of 45 other Cigarette Smoking trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cigarette Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01526005, the US trial registry maintained by the National Library of Medicine. NCT01526005 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.